PL375742A1 - Method of treating osteoarthritis - Google Patents

Method of treating osteoarthritis

Info

Publication number
PL375742A1
PL375742A1 PL03375742A PL37574203A PL375742A1 PL 375742 A1 PL375742 A1 PL 375742A1 PL 03375742 A PL03375742 A PL 03375742A PL 37574203 A PL37574203 A PL 37574203A PL 375742 A1 PL375742 A1 PL 375742A1
Authority
PL
Poland
Prior art keywords
treating osteoarthritis
osteoarthritis
treating
Prior art date
Application number
PL03375742A
Other languages
Polish (pl)
Inventor
Joseph Anthony Cornicelli
Kenneth Stanley Kilgore
Drago Robert Sliskovic
Susan Elizabeth Bove
David Herbert Neideffer
Mark Charles Kowala
Original Assignee
Warner-Lambert Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company Llc filed Critical Warner-Lambert Company Llc
Publication of PL375742A1 publication Critical patent/PL375742A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
PL03375742A 2002-08-22 2003-08-13 Method of treating osteoarthritis PL375742A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40525002P 2002-08-22 2002-08-22

Publications (1)

Publication Number Publication Date
PL375742A1 true PL375742A1 (en) 2005-12-12

Family

ID=31946834

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03375742A PL375742A1 (en) 2002-08-22 2003-08-13 Method of treating osteoarthritis

Country Status (13)

Country Link
EP (1) EP1539127A1 (en)
JP (1) JP2006501238A (en)
KR (1) KR20050058454A (en)
CN (1) CN1678297A (en)
AU (1) AU2003255937A1 (en)
BR (1) BR0313883A (en)
CA (1) CA2494544A1 (en)
IL (1) IL166600A0 (en)
MX (1) MXPA05001254A (en)
PL (1) PL375742A1 (en)
TW (1) TW200410677A (en)
WO (1) WO2004017952A1 (en)
ZA (1) ZA200501133B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004105801A1 (en) * 2003-05-30 2004-12-09 Warner-Lambert Company Llc Animal model for the alleviation of pain using il-6
WO2005002557A1 (en) * 2003-07-03 2005-01-13 Warner-Lambert Company Llc Pharmaceutical compositions including an ether and selective cox-2 inhibitor and uses thereof
US20050026979A1 (en) * 2003-07-31 2005-02-03 Maha Ghazzi Methods for treating inflammation and inflammation-associated diseases with a statin and ether
DE102008000237A1 (en) 2007-02-06 2008-08-07 Basf Se Mixtures, useful e.g. as an inhibitor or retarder for the stabilization of polymerizable compound, preferably swellable hydrogel-forming polymers, comprises a phenol imidazole derivative and a polymerizable compound
IL181577A0 (en) * 2007-02-26 2007-07-04 Jacob Bar Tana Combination therapy composition and methods for the treatment of cardiovascular disorders and immune-related disorders
US8530420B2 (en) * 2008-12-16 2013-09-10 Kaohsiung Medical University Treatment of arthritis with parathyroid hormone
TWI382841B (en) * 2010-10-29 2013-01-21 Univ China Medical Pharmaceutical composition for inhibiting inflammation
KR20200054910A (en) * 2017-04-18 2020-05-20 젬파이어 세러퓨틱스 인코포레이티드 Gemcarbine, pharmaceutically acceptable salts, compositions and methods of use thereof
US20200253877A1 (en) * 2018-10-18 2020-08-13 Neurobo Pharmaceuticals, Inc. Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor
CN114847223B (en) * 2022-02-19 2023-11-07 昆明理工大学 Method for establishing OA cynomolgus monkey model

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648387A (en) * 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
JP4750995B2 (en) * 2000-01-25 2011-08-17 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー Calcium dicarboxylate ether, process for producing the same, and treatment of vascular diseases and diabetes using the same
US20030220374A1 (en) * 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors

Also Published As

Publication number Publication date
BR0313883A (en) 2005-07-19
CA2494544A1 (en) 2004-03-04
AU2003255937A1 (en) 2004-03-11
TW200410677A (en) 2004-07-01
MXPA05001254A (en) 2005-06-08
JP2006501238A (en) 2006-01-12
IL166600A0 (en) 2006-01-15
ZA200501133B (en) 2008-01-30
KR20050058454A (en) 2005-06-16
WO2004017952A1 (en) 2004-03-04
CN1678297A (en) 2005-10-05
EP1539127A1 (en) 2005-06-15

Similar Documents

Publication Publication Date Title
AU2003226301A8 (en) Method of treating cancer
AU2003293333A8 (en) Method of treating cancers
AU2003256847A8 (en) Method of treating cancer
IL166600A0 (en) Method of treating osteoarthritis
AU2003278361A1 (en) Method of water treatment
AU2003283958A8 (en) Method of treating tremors
IL165304A0 (en) Method of treating diabetes
EP1577280A4 (en) Method of deuterization
EP1575606A4 (en) Treatment of osteoarthritis
GB0306309D0 (en) Method of treatment
EP1389105A4 (en) Method of treatment
GB0302572D0 (en) Method of treatment
AUPS201002A0 (en) Method of treating shellfish
GB0112216D0 (en) Method of treatment
EP1553965A4 (en) Method of treating tumors
EP1493716A4 (en) Method of wastewater treatment
AU2003248584A1 (en) Method of treating osteoarthritis
GB0118892D0 (en) Method of treatment
GB0208897D0 (en) New method of treatment
PL376350A1 (en) Sludge treatment method
AU2003225563A8 (en) Compositions and methods for treatment of osteoarthritis
EP1688503A4 (en) Method of treating cells
AU2002951913A0 (en) Method of treatment
GB0213198D0 (en) Method of treatment
GB0207091D0 (en) Method of treatment

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)